Fluorescent signals were stronger in HT-29–TRPV2 tumours than in HT-29 tumours throughout 48-h observations, suggesting sustained targeting of TRPV2–PCNH nanoparticles to TRPV2 overexpressing tumours (Supplementary Fig. 10b). The gene discussed is TRPV2; the disease is neoplasm.